MA33022B1 - Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil - Google Patents

Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil

Info

Publication number
MA33022B1
MA33022B1 MA33942A MA33942A MA33022B1 MA 33022 B1 MA33022 B1 MA 33022B1 MA 33942 A MA33942 A MA 33942A MA 33942 A MA33942 A MA 33942A MA 33022 B1 MA33022 B1 MA 33022B1
Authority
MA
Morocco
Prior art keywords
produce
odiphenyl
mixture
order
textured
Prior art date
Application number
MA33942A
Other languages
Arabic (ar)
English (en)
Inventor
Moo-Hi Yoo
Bong-Jin Cha
Jeong-Hoon Kim
Sun-Woo Jang
Sang-Dug Han
Original Assignee
Dong Apharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Apharm Co Ltd filed Critical Dong Apharm Co Ltd
Publication of MA33022B1 publication Critical patent/MA33022B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION À LIBÉRATION CONTRÔLÉE POUR PRODUIRE UNE PRÉPARATION À LIBÉRATION PROLONGÉE CONTENANT DE L'UDÉNAFIL. PLUS PARTICULIÈREMENT, LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION À LIBÉRATION CONTRÔLÉE POUR PRODUIRE UNE PRÉPARATION À LIBÉRATION PROLONGÉE CONTENANT DE L'UDÉNAFIL, LADITE COMPOSITION CONTENANT (A) DE L'UDÉNAFIL ET UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, (B) UN MODULATEUR DE SOLUBILITÉ, (C) UN ADSORBANT, ET (D) UN POLYMÈRE HYDROPHILE. LA COMPOSITION À LIBÉRATION CONTRÔLÉE POUR PRODUIRE UNE PRÉPARATION À LIBÉRATION PROLONGÉE CONTENANT DE L'UDÉNAFIL SELON LA PRÉSENTE INVENTION LIBÈRE DES MÉDICAMENTS CONSTAMMENT QUEL QUE SOIT LE NIVEAU DE PH DANS LE TRACTUS GASTRO-INTESTINAL, ET AINSI RÉGULE LIBREMENT LA DURÉE DE LIBÉRATION DE MÉDICAMENT DANS LA PLAGE DE 3 À 24 HEURES, ET RÉDUIT LA VARIABILITÉ DE L'EFFET DE MÉDICAMENTS ENTRE INDIVIDUS. DE PLUS, LA COMPOSITION DE LA PRÉSENTE INVENTION PEUT ÊTRE PRODUITE DANS UNE PRÉPARATION À LIBÉRATION PROLONGÉE QUI A UNE CONDITION OPTIMALE POUR EXPRIMER L'EFFET DE MÉDICAMENTS DANS LE TRAITEMENT DE MALADIES TELLES QUE L'HYPERTENSION ARTÉRIELLE PULMONAIRE, L'HYPERTENSION PORTALE HÉPATIQUE, UNE HYPERPLASIE PROSTATIQUE BÉNIGNE, ET SIMILAIRE, QUI PEUVENT ÊTRE TRAITÉES PAR L'UDÉNAFIL ET QUI REQUIÈRENT L'ADMINISTRATION DE MÉDICAMENTS SUR UNE LONGUE DURÉE. LA COMPOSITION DE LA PRÉSENTE INVENTION PEUT RÉGULER LA LIBÉRATION DE MÉDICAMENTS EN FONCTION DU TEMPS NÉCESSAIRE POUR L'ABSORPTION DE CEUX-CI LORSQUE LESDITS MÉDICAMENTS SONT ADMINISTRÉS À UN CORPS VIVANT, ET AINSI PEUVENT ÊTRE UTILISÉS DE MANIÈRE BÉNÉFIQUE DANS LA PRÉVENTION ET LE TRAITEMENT D'UN TROUBLE DE L'ÉRECTION.
MA33942A 2008-12-17 2009-12-10 Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil MA33022B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080128499A KR101004205B1 (ko) 2008-12-17 2008-12-17 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
PCT/KR2009/007382 WO2010071320A2 (fr) 2008-12-17 2009-12-10 Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil

Publications (1)

Publication Number Publication Date
MA33022B1 true MA33022B1 (fr) 2012-02-01

Family

ID=42269213

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33942A MA33022B1 (fr) 2008-12-17 2009-12-10 Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil

Country Status (14)

Country Link
US (1) US20110250279A1 (fr)
EP (1) EP2374479A4 (fr)
JP (1) JP2012512242A (fr)
KR (1) KR101004205B1 (fr)
CN (1) CN102307597A (fr)
AU (1) AU2009327758A1 (fr)
BR (1) BRPI0923003A2 (fr)
CA (1) CA2746190A1 (fr)
MA (1) MA33022B1 (fr)
MX (1) MX2011006450A (fr)
RU (1) RU2480240C2 (fr)
SG (1) SG172084A1 (fr)
WO (1) WO2010071320A2 (fr)
ZA (1) ZA201104445B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102871997B (zh) * 2011-07-12 2013-11-13 山东绿叶制药有限公司 含有去甲基文拉法辛苯甲酸酯类化合物的缓释药物组合物
WO2014078435A1 (fr) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions contenant un matériau biologiquement actif et un oxyde inorganique non ordonné
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3180008B1 (fr) 2014-08-12 2023-11-29 Mezzion Pharma Co., Ltd. Procédés d'amélioration de la performance du myocarde chez des patients opérés d'un fontan, au moyen de compositions d'udénafil
WO2016168077A1 (fr) * 2015-04-16 2016-10-20 Bpsi Holdings, Llc Compositions d'oxyde de polyéthylène stabilisé
KR102249155B1 (ko) * 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0136527Y1 (ko) 1993-11-30 1999-03-20 이대원 와이어 본딩 헤드
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
EP1104290B1 (fr) * 1998-08-13 2010-03-31 Cima Labs Inc. Microemulsions comme formes pharmaceutiques solides destinees a une administration orale
PT1039882E (pt) 1998-08-27 2011-01-03 Pfizer Health Ab Formulação terapêutica para administrar tolterodina com libertação controlada
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
JP2002539165A (ja) * 1999-03-16 2002-11-19 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 舌下またはバッカル投与により送出されるシルデナフィルの制御放出
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
NZ518281A (en) 1999-12-23 2005-01-28 Pfizer Prod Inc Controlled release drug dosage core comprising a drug-containing composition and a water-swellable composition
WO2003000238A1 (fr) 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de produits d'adsorption de medicament amorphe
CA2450957A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
KR200270330Y1 (ko) 2001-10-09 2002-04-03 이대범 퍼머용 아이롱
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
DE102004027743A1 (de) 2004-06-07 2006-01-05 Fresenius Medical Care Deutschland Gmbh Kappe, insbesondere Desinfektionskappe, Detektionsvorrichtung für die Peritonealdialyse, Beutelset für die Peritonealdialyse und dessen Verwendung
CA2600282A1 (fr) 2005-03-29 2006-10-05 Roehm Gmbh Forme pharmaceutique multiparticulaire constituee de pellets renfermant une substance ayant un effet modulaire sur la liberation de l'ingredient actif
MX2008000087A (es) * 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
KR100912680B1 (ko) * 2006-03-16 2009-08-19 (주) 벡스코아 제어 방출 제형
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101304343B1 (ko) * 2006-04-06 2013-09-11 한미사이언스 주식회사 Ｐｄｅ-5 억제제의 경구용 속용제형
KR100780479B1 (ko) * 2006-05-08 2007-11-28 윈셋파마 주식회사 이부딜라스트 함유 경구용 제제 및 이의 제조방법
KR100791844B1 (ko) * 2006-06-30 2008-01-07 주식회사유한양행 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
KR200483492Y1 (ko) 2015-03-31 2017-05-22 산제트 인터내셔널 컴퍼니, 리미티드 공작기계의 지능형 제어 시스템

Also Published As

Publication number Publication date
BRPI0923003A2 (pt) 2015-12-15
RU2480240C2 (ru) 2013-04-27
KR101004205B1 (ko) 2010-12-24
ZA201104445B (en) 2012-03-28
US20110250279A1 (en) 2011-10-13
WO2010071320A3 (fr) 2010-09-30
JP2012512242A (ja) 2012-05-31
MX2011006450A (es) 2011-07-28
EP2374479A4 (fr) 2012-09-12
RU2011129643A (ru) 2013-01-27
EP2374479A2 (fr) 2011-10-12
AU2009327758A1 (en) 2011-07-07
WO2010071320A2 (fr) 2010-06-24
CA2746190A1 (fr) 2010-06-24
SG172084A1 (en) 2011-07-28
CN102307597A (zh) 2012-01-04
KR20100069939A (ko) 2010-06-25

Similar Documents

Publication Publication Date Title
MY153921A (en) Aminopyrazole derivatives
HK1128471A1 (en) Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
MX2010004576A (es) Derivados de pirimidina novedosos.
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
MX2009009597A (es) Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
MY154909A (en) Novel thiophene derivatives
WO2007098128A3 (fr) Formules liquides de phényléphrine
MY149869A (en) Thiophene derivatives as s1p1/edg1 receptor agonists
MY153985A (en) Aminotriazole derivatives as alx agonists
ZA200807274B (en) Novel pyridine derivatives
DOP2011000354A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
MX2010001881A (es) Derivados de piridina como moduladores del receptor s1p1/edg1.
WO2009063222A3 (fr) Compositions solides
MA33022B1 (fr) Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TW200942524A (en) Novel aminomethyl benzene derivatives
ECSP088889A (es) Forma nueva de administración de racecadotril
JO2831B1 (en) Quinclidine carbonate derivatives and pharmaceutical compounds
TW200942530A (en) Pyridine compounds
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
EA200601759A1 (ru) Композиции рамиприла
MX2009010689A (es) Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
MX2007006042A (es) Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparacion, composiciones que las contienen y utilizacion.
HK1104823A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
UY31758A (es) Forma cristalina anhidra de maleato de orvepitant